Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2009 Aug 11;8(8):2204–2210. doi: 10.1158/1535-7163.MCT-09-0160

Figure 4. NVP-BEZ235 treatment prolongs survival of animals with intracranial xenografts.

Figure 4

(A) Top panel: The Kaplan-Meier survival curve for the U87 xenograft experiment, with a p value of 0.026. The p values in the plot determined by the log-rank test are for the comparison of the overall survival of the vehicle-treated mice with that of the NVP-BEZ235-treated mice. (B) Weight measurements of experimental animals ar regular intervals. (C) Tumor volumes of intracranial tumors were measured at the time of sacrifice. The mean tumor volume was reduced in treated animal with NVP-BEZ235. (D) Immunoblotting analyses to assess LC3-II expression after 2-week and 4-week tumor cell extracts following NVP-BEZ235 treatment. The increase in ratio of LC3-II/LC3-I is an indication of autophagy in NVP-BEZ235 treated tumors in comparison to vehicle treated animals. (E) Immunoblotting analyses of both the expression and activation of Akt and S6K1 in 2-week and 4-week tumors following NVP-BEZ235 treatment. Immunoblotting analyses demonstrated that NVP-BEZ235 inhibited the activity of S6K1 in both sets of tumors, as assessed by the level of corresponding phosphorylated protein.